<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02440802</url>
  </required_header>
  <id_info>
    <org_study_id>B403201317385</org_study_id>
    <nct_id>NCT02440802</nct_id>
  </id_info>
  <brief_title>Evaluation and Predictive Value of Genetic Polymorphisms in the Management of Hormonal Treatment of Prostate Cancer</brief_title>
  <acronym>Feel+</acronym>
  <official_title>Evaluation and Predictive Value of Genetic Polymorphisms in the Management of Hormonal Treatment of Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Androgen deprivation therapy (ADT) by surgical castration or administration of LHRH agonists
      or antagonists is the gold-standard systemic treatment of Prostate Cancer. The efficacy,
      severity and frequency of side effects of ADT vary from a patient to another. The exact cause
      of this variability is not known, however certain genetic polymorphisms affecting enzymes
      implicated in the synthesis and metabolism of sex-steroids seem to be involved in these
      processes.

      To perform a longitudinal study to evaluate the prevalence of various genetic polymorphisms
      affecting genes in the sex-steroid synthesis and metabolism pathway (CYP1A1, CYP1B1, CYP19A1,
      17HSD, HSD3B1, AR, ESR1, ESRRG, IL6, TNF-alpha) in men with Prostate Cancer receiving ADT and
      the possible association between polymorphisms and frequency and severity of side-effects of
      ADT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prostate cancer patients for which reimbursed ADT with a gonadoliberin antagonist is
      indicated, for a period of at least 6 months will lbe enrolled. At 0, 3 months and 6 months
      of ADT, Aging Males' Symptoms (AMS), EQ-5D (EuroQoL), and hot flashes intensity and frequency
      (Moyad scale) will be collected, as well as routine assessments: vital signs (blood pressure,
      heart rate), weight, waist perimeter, fat percentage, Body Mass Index (BMI) and routine
      laboratory assessments. Determine genotypes of polymorphisms of interest by pyrosequencing.
      Determine the prevalence of the polymorphisms of interest in the studied population. Perform
      initial assessment of the association between genetic polymorphisms and questionnaire
      results.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Aging Males Symptoms questionnaire</measure>
    <time_frame>0 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Aging Males Symptoms questionnaire</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Aging Males Symptoms questionnaire</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Gonadoliberin antagonist treatment</arm_group_label>
    <description>Single arm study, all patients are treated the same way. Saliva sample collection for genetic analyses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Saliva sample collection for genetic analyses</intervention_name>
    <description>Patients with Prostate cancer receiving androgen deprivation treatment with a GnRH antagonist will be followed-up for 6 months for quality of life. At Baseline, 3 months and 6 months of treatment QoL data will be collected, as well as body parameters. At Baseline, once, a saliva sample will be collected for genetic analyses.</description>
    <arm_group_label>Gonadoliberin antagonist treatment</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      One saliva sample (2mL) will be collected once at baseline for single nucleotide polymorphism
      analyses.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Prostate cancer patients for which reimbursed androgen deprivation therapy with a
        gonadoliberin antagonist is indicated, for aperiod of at least 6 months.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prostate cancer patients for which reimbursed ADT with a gonadoliberin antagonist is
             indicated, for a period of at least 6 months.

        Exclusion Criteria:

          -  Prostate cancer patients who are already receiving ADT with a gonadoliberin
             antagonist.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertrand TOMBAL, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques Universitaires Saint Luc, Brussels</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bertrand TOMBAL, MD, PhD</last_name>
    <phone>003227641409</phone>
    <email>bertrand.tombal@uclouvain.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valentina BUTOESCU, PharmD</last_name>
    <phone>003227643546</phone>
    <email>valentina.butoescu@uclouvain.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ASZ Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard RAPPE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>OLV Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter SCHATTEMAN, MD</last_name>
      <email>peter.schatteman@olvz-aalst.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tibaut DEBACKER, MD</last_name>
      <email>tibaut.debacker@zna.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHu Saint Pierre</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Entezari, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry ROUMEGUERE, MD</last_name>
      <email>Thierry.Roumeguere@erasme.ulb.ac.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand TOMBAL, MD, PhD</last_name>
      <phone>003227641409</phone>
      <email>bertrand.tombal@uclouvain.be</email>
    </contact>
    <contact_backup>
      <last_name>Valentina BUTOESCU, PharmD</last_name>
      <phone>003227643546</phone>
      <email>valentina.butoescu@uclouvain.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>AZ Sint Blasius</name>
      <address>
        <city>Dendermonde</city>
        <zip>9200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dieter OST, MD</last_name>
      <email>dieter.ost@azsintblasius.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JESSA Ziekenhuis</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kris VEKEMANS, MD</last_name>
      <email>kris.vekemans@jessazh.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jan Ypermanziekenhuis</name>
      <address>
        <city>Ieper</city>
        <zip>8900</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>CHU Tivoli</name>
      <address>
        <city>La Louviere</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry WILDSCHUTZ, MD</last_name>
      <email>thierry.wildschutz@chu-tivoli.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHR Citadelle</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hubert NICOLAS, MD</last_name>
      <email>hubert.nicolas@chrcitadelle.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Sint Jozef</name>
      <address>
        <city>Malle</city>
        <zip>2390</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>ZNA Jan Palfijn</name>
      <address>
        <city>Merksem</city>
        <zip>2170</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter DE JONGE, MD</last_name>
      <email>peter.dejonge@zna.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Mouscron</name>
      <address>
        <city>Mouscron</city>
        <zip>7700</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe FRANCOIS, MD</last_name>
      <email>philippe.francois@chmouscron.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Luc Bouge</name>
      <address>
        <city>Namur</city>
        <zip>5004</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luc DE VISSCHER, MD</last_name>
      <email>luc.devischher@slbo.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Damiaan</name>
      <address>
        <city>Oostende</city>
        <zip>8400</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pieter MATTELAER, MD</last_name>
      <email>pmattelaer@azdamiaan.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Delta</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lieven GOEMAN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ St Jozef</name>
      <address>
        <city>Turnhout</city>
        <zip>2300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koen Ackaert, MD</last_name>
      <email>koen.ackaert@azturnhout.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Jan Portaels</name>
      <address>
        <city>Vilvoorde</city>
        <zip>1800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geert Martens, MD</last_name>
      <email>geert@urovil.eu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Mont-Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis LORGE, MD</last_name>
      <email>francis.lorge@uclouvain.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011 Apr;59(4):572-83. doi: 10.1016/j.eururo.2011.01.025. Epub 2011 Jan 25.</citation>
    <PMID>21315502</PMID>
  </reference>
  <reference>
    <citation>Mohile SG, Mustian K, Bylow K, Hall W, Dale W. Management of complications of androgen deprivation therapy in the older man. Crit Rev Oncol Hematol. 2009 Jun;70(3):235-55. doi: 10.1016/j.critrevonc.2008.09.004. Epub 2008 Oct 25. Review.</citation>
    <PMID>18952456</PMID>
  </reference>
  <reference>
    <citation>Allain TJ. Prostate cancer, osteoporosis and fracture risk. Gerontology. 2006;52(2):107-10. Review.</citation>
    <PMID>16508318</PMID>
  </reference>
  <reference>
    <citation>Benton MJ, White A. Osteoporosis: recommendations for resistance exercise and supplementation with calcium and vitamin D to promote bone health. J Community Health Nurs. 2006 Winter;23(4):201-11. Review.</citation>
    <PMID>17064230</PMID>
  </reference>
  <reference>
    <citation>Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer. 2004 Mar 1;100(5):892-9. Review.</citation>
    <PMID>14983482</PMID>
  </reference>
  <reference>
    <citation>McGrath SA, Diamond T. Osteoporosis as a complication of orchiectomy in 2 elderly men with prostatic cancer. J Urol. 1995 Aug;154(2 Pt 1):535-6.</citation>
    <PMID>7609129</PMID>
  </reference>
  <reference>
    <citation>Oefelein MG, Ricchuiti V, Conrad W, Seftel A, Bodner D, Goldman H, Resnick M. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol. 2001 Nov;166(5):1724-8.</citation>
    <PMID>11586210</PMID>
  </reference>
  <reference>
    <citation>Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006 Aug 20;24(24):3979-83.</citation>
    <PMID>16921050</PMID>
  </reference>
  <reference>
    <citation>Galvão DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T, Rowling C, Prince R. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int. 2008 Jul;102(1):44-7. doi: 10.1111/j.1464-410X.2008.07539.x. Epub 2008 Mar 11. Erratum in: BJU Int. 2008 Aug;102(3):418.</citation>
    <PMID>18336606</PMID>
  </reference>
  <reference>
    <citation>Galvão DA, Taaffe DR, Spry N, Joseph D, Turner D, Newton RU. Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis. 2009;12(2):198-203. doi: 10.1038/pcan.2008.51. Epub 2008 Oct 14.</citation>
    <PMID>18852703</PMID>
  </reference>
  <reference>
    <citation>Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL, Finkelstein JS. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer. 2008 May 15;112(10):2188-94. doi: 10.1002/cncr.23440.</citation>
    <PMID>18348297</PMID>
  </reference>
  <reference>
    <citation>Smith MR, O'Malley AJ, Keating NL. Gonadotrophin-releasing hormone agonists, diabetes and cardiovascular disease in men with prostate cancer: which metabolic syndrome? BJU Int. 2008 Jun;101(11):1335-6. doi: 10.1111/j.1464-410X.2008.07707.x.</citation>
    <PMID>18454791</PMID>
  </reference>
  <reference>
    <citation>D'Amico AV, Denham JW, Bolla M, Collette L, Lamb DS, Tai KH, Steigler A, Chen MH. Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate. Cancer. 2007 May 15;109(10):2004-10.</citation>
    <PMID>17397033</PMID>
  </reference>
  <reference>
    <citation>D'Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, Joseph D, Tai KH, Malone S, Ludgate C, Steigler A, Kantoff PW. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007 Jun 10;25(17):2420-5.</citation>
    <PMID>17557956</PMID>
  </reference>
  <reference>
    <citation>D'Amico AV, Loffredo M, Renshaw AA, Loffredo B, Chen MH. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level. J Clin Oncol. 2006 Sep 1;24(25):4190-5.</citation>
    <PMID>16943536</PMID>
  </reference>
  <reference>
    <citation>Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol. 2009 Jan 1;27(1):92-9. doi: 10.1200/JCO.2007.12.3752. Epub 2008 Dec 1.</citation>
    <PMID>19047297</PMID>
  </reference>
  <reference>
    <citation>Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, Taplin ME, Regan MM, Kantoff PW, Freedman M. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2008 Feb 20;26(6):842-7. doi: 10.1200/JCO.2007.13.6804.</citation>
    <PMID>18281655</PMID>
  </reference>
  <reference>
    <citation>Jim HS, Park JY, Permuth-Wey J, Rincon MA, Phillips KM, Small BJ, Jacobsen PB. Genetic predictors of fatigue in prostate cancer patients treated with androgen deprivation therapy: preliminary findings. Brain Behav Immun. 2012 Oct;26(7):1030-6. doi: 10.1016/j.bbi.2012.03.001. Epub 2012 Mar 28.</citation>
    <PMID>22475653</PMID>
  </reference>
  <reference>
    <citation>Shearman AM, Cupples LA, Demissie S, Peter I, Schmid CH, Karas RH, Mendelsohn ME, Housman DE, Levy D. Association between estrogen receptor alpha gene variation and cardiovascular disease. JAMA. 2003 Nov 5;290(17):2263-70. Erratum in: JAMA. 2004 Jan 14;291(2):186.</citation>
    <PMID>14600184</PMID>
  </reference>
  <reference>
    <citation>Alevizaki M, Cimponeriu AT, Garofallaki M, Sarika HL, Alevizaki CC, Papamichael C, Philippou G, Anastasiou EA, Lekakis JP, Mavrikakis M. The androgen receptor gene CAG polymorphism is associated with the severity of coronary artery disease in men. Clin Endocrinol (Oxf). 2003 Dec;59(6):749-55.</citation>
    <PMID>14974917</PMID>
  </reference>
  <reference>
    <citation>Fox CS, Yang Q, Cupples LA, Guo CY, Atwood LD, Murabito JM, Levy D, Mendelsohn ME, Housman DE, Shearman AM. Sex-specific association between estrogen receptor-alpha gene variation and measures of adiposity: the Framingham Heart Study. J Clin Endocrinol Metab. 2005 Nov;90(11):6257-62. Epub 2005 Sep 6.</citation>
    <PMID>16144952</PMID>
  </reference>
  <reference>
    <citation>Elfassihi L, Giroux S, Bureau A, Laflamme N, Cole DE, Rousseau F. Association with replication between estrogen-related receptor gamma (ESRRgamma) polymorphisms and bone phenotypes in women of European ancestry. J Bone Miner Res. 2010 Apr;25(4):901-11. doi: 10.1359/jbmr.091014.</citation>
    <PMID>19821770</PMID>
  </reference>
  <reference>
    <citation>Crandall CJ, Crawford SL, Gold EB. Vasomotor symptom prevalence is associated with polymorphisms in sex steroid-metabolizing enzymes and receptors. Am J Med. 2006 Sep;119(9 Suppl 1):S52-60.</citation>
    <PMID>16949389</PMID>
  </reference>
  <reference>
    <citation>Rodríguez-González G, Ramírez-Moreno R, Pérez P, Bilbao C, López-Ríos L, Díaz-Chico JC, Lara PC, Serra-Majem L, Chirino R, Díaz-Chico BN. The GGN and CAG repeat polymorphisms in the exon-1 of the androgen receptor gene are, respectively, associated with insulin resistance in men and with dyslipidemia in women. J Steroid Biochem Mol Biol. 2009 Feb;113(3-5):202-8. doi: 10.1016/j.jsbmb.2008.12.009. Epub 2008 Dec 30.</citation>
    <PMID>19159685</PMID>
  </reference>
  <reference>
    <citation>Moyad MA. Promoting general health during androgen deprivation therapy (ADT): a rapid 10-step review for your patients. Urol Oncol. 2005 Jan-Feb;23(1):56-64. Review.</citation>
    <PMID>15885584</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2015</study_first_submitted>
  <study_first_submitted_qc>May 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2015</study_first_posted>
  <last_update_submitted>October 17, 2016</last_update_submitted>
  <last_update_submitted_qc>October 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

